Market capitalization | $7.60b |
Enterprise Value | $5.50b |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.66 |
Free Cash Flow (TTM) Free Cash Flow | $-601.72m |
Cash position | $2.10b |
P/E forward | negative |
P/S forward | 1,331.01 |
EV/Sales forward | 962.66 |
As a Free StocksGuide user, you can view scores for all 6,836 stocks worldwide.
13 Analysts have issued a Revolution Medicines Inc forecast:
13 Analysts have issued a Revolution Medicines Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -685 -685 |
42%
42%
|
EBIT (Operating Income) EBIT | -692 -692 |
42%
42%
|
Net Profit | -600 -600 |
38%
38%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.
Head office | United States |
CEO | Mark Goldsmith |
Employees | 534 |
Founded | 2004 |
Website | www.revmed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.